Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression

NCT07155226 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

84

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Lymphoblastic Leukaemia
Acute Myeloid Leukaemia
Higher-risk Myelodysplastic Syndromes

Interventions

DRUG: AZD3632
DRUG: Posaconazole

Sponsor

AstraZeneca